Janssen Submits Guselkumab Application to the EMA

Janssen has filed its drug candidate for psoriasis, guselkumab, with the EMA.

Guselkumab is a human antibody that targets the protein interleukin, which has a key role in the development of immune-mediated inflammatory diseases.

The filing is based on safety and efficacy data gathered from four studies on the drug candidate.

The drug targets moderate to severe forms of the disease, which accounts for around 20 percent of all cases.